Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole vs Caspofungin for Empiric Antifungal Therapy in Neutropenic Fever
NCT02895529Phase 4Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2016
- Primary completion
- May 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of itraconazole in fungal infection (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Response Rate Measured by the Percentage of Participants That Achieve all of the Following 5 Composite Endpoints up to 36 days. Started Nov 2016; status: terminated.
02
Drugs
itraconazole
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT02895529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02895529.